Hemispherian AS is a biotechnology company located in Oslo. Hemispherian is advancing first-in-class therapeutics for the indication with the greatest unmet need in oncology — glioblastoma multiforme. Patients diagnosed with glioblastoma multiforme have dismal outcomes. Overall survival is measured in months with quality of life deteriorating rapidly. It is Hemispherian’s mission to provide superior treatment options.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
GLIX1: Pharmaceutical for Glioblastoma Multiforme
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):